APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2001
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with biological therapy may kill more cancer cells.
Epistemonikos ID: bab5f42bf35970c57703b38628e3cc4f14a7134d
First added on: May 03, 2024